News

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Texas Biomed taps new research leadership to help craft aggressive game plan

Joanne Turner has joined Texas Biomedical Research Institute as its new vice president of research. COURTESY ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
San Antonio bioscience company Xenex secures major funding
January 27, 2015

U.S. Air Force Hospital Langley recently received a germ-zapping robot from Xenex Disinfection Services that can disinfect a room from bacteria and viruses in five to 10 minutes, company officials said. (Photo by Joe Fudge)

By W. Scott Bailey, San Antonio Business Journal

Xenex Disinfection Services has secured $25 million in new funding from multiple investors. The San Antonio-based company, which has seen increased interest among health care facilities for its robotic germ-zapping device, will use the new capital to fund product development, international expansion and a larger sales force.

Xenex officials said decreased reimbursements and increased scrutiny for hospitals dealing with health care-associated infections have driven up demand for the company's patented pulsed xenon device, which eliminates deadly microorganisms that can cause serious hospital-acquired infections, or HAIs. Concerns about the spread of Ebola have further fueled demand for the device.

"Hospital-acquired infections are a global problem, and we have proven that the use of our germ-zapping robot provides a cleaner, and therefore safer health care environment," Xenex CEO Morris Miller said in a news release.

In October Miller told me, "The arrival of Ebola in the U.S. has served as a wake-up call for our hospitals and the (Centers for Disease Control and Prevention) that current infection-prevention efforts aren't enough. There's been a significant spike in interest for our germ-zapping robots."

Some of the latest Xenex funding comes from a new investor - Brandon Point Industries Ltd., a life sciences company based in Ireland. The balance is from current Xenex investors, including Battery Ventures, Targeted Technology Fund II and RK Ventures.

Brandon Point co-founder Kelly Martin said Xenex's unique technology addresses "important and immediate patient and health care worker needs" at a time when there are growing concerns about "worldwide disease outbreaks."

Xenex's robotic device can disinfect hospital rooms and other medical areas in a matter of minutes, company officials said. More than 250 hospitals and Veterans Affairs and Department of Defense facilities in the U.S. are using Xenex robots.

Stay informed. Subscribe to BioMed SA news alerts.